Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aminophylline + acetaminophen is a combination therapy being evaluated by Sargodha Medical College for the prevention of post-dural puncture headache (PDPH). Aminophylline, a methylxanthine derivative, acts as a non-selective adenosine receptor antagonist and phosphodiesterase inhibitor; in the context of PDPH, it is thought to alleviate symptoms by promoting cerebral vasoconstriction and potentially stimulating cerebrospinal fluid production. Acetaminophen is a non-opioid analgesic that provides pain relief through the inhibition of cyclooxygenase enzymes in the central nervous system. This combination is administered intravenously as a slow infusion for prophylactic use in surgical patients with a history of PDPH.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aminophylline + acetaminophen.